EKF Diagnostics Holdings PLC Notice of Results (9258Q)
March 03 2021 - 01:00AM
UK Regulatory
TIDMEKF
RNS Number : 9258Q
EKF Diagnostics Holdings PLC
03 March 2021
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014
(MAR)
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Notice of results
Investor presentation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed
point-of-care business, will announce its preliminary results for
the year ended 31 December 2020 on Tuesday 30 March 2021.
Investor briefing
EKF Diagnostics will be hosting a live online presentation open
to all investors on Tuesday 30 March 2021 at 4.30pm, via video
conference call. If you would like to register, please contact
Walbrook PR on 020 7933 8780
or email ekf@walbrookpr.com
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-executive Chairman Tel: +44 (0) 29 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer Tel: 020 7496 3000
Aubrey Powell / George Tzimas (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0) 7980 541 893 / +44 (0) 7584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF Diagnostics Holdings plc specialises in the development,
production and worldwide distribution of point-of-care analyzers
and clinical chemistry reagents for use in hospital and research
laboratories, doctor's offices, blood banks and for in-field
anaemia screening programmes. EKF is also a bulk manufacturer of
enzymes and has custom manufacturing facilities in the USA for a
variety of life science products.
In 2020, EKF developed a range of COVID-19 testing products
including PrimeStore MTM, an FDA-approved and CE marked sample
containment device that allows the safe handling, transportation
and analysis of test swabs and samples, which it manufactures under
licence, and COVID-SeroKlir, a leading ELISA-based antibody test
from Kantaro Biosciences that provides a precise measurement of
COVID-19 IgG antibodies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORMZGGFNZVGMZM
(END) Dow Jones Newswires
March 03, 2021 02:00 ET (07:00 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2023 to Mar 2024